A wall by a window with a neon sign reading 'It's hard to know your patients' HAE is well controlled' with a switch. A wall by a window with a neon sign reading 'It's hard to know your patients' HAE is well controlled' with a switch.

FLIP THE SWITCH™ on your expectations of
hereditary angioedema (HAE)
prophylactic treatment.

See the results

An attack-free year is possible with
DAWNZERA1

OASIS-HAE was a double-blind, placebo-controlled 6-month study (N=90)2,3*:

  • Mean monthly HAE attack rate at Week 24 with DAWNZERA every 4 weeks was 0.44 vs 2.26 for placebo, an attack reduction of 81% (P<0.001, primary endpoint)
  • This increased to an 87% reduction when measured from the second dose (0.30 vs 2.25 for placebo, P<0.001, secondary endpoint)2,3:
94% mean attack reduction at 1 year of taking DAWNZERA in the open-label study.
* Enrolled patients aged ≥12 years with HAE type 1 or 2. Patients received DAWNZERA every 4 weeks (n=45), DAWNZERA every 8 weeks (n=23), or placebo every 4 or 8 weeks (n=22).2
† Ongoing open-label safety (primary endpoint) and efficacy (secondary endpoint) extension OASISplus trial. 83 patients were included in this 52-week interim analysis. Data cut-off: January 27, 2025.1,4
94% mean attack reduction at 1 year of taking DAWNZERA in the open-label study.
Results in patients who switched to DAWNZERA5
Reductions in mean HAE attack rate were observed in patients switching from lanadelumab, berotralstat, or a C1-INH in an interim analysis at Week 16 in an ongoing open-label study
See more switch results
DAWNZERA targeting RNA icon
The first and only RNA-targeted treatment for patients with HAE2,6
DAWNZERA has the selectivity of RNA technology and does not irreversibly edit DNA.6,7
See how it works
Icon of computer with a prescription symbol and cursor.
Getting DAWNZERA
We help provide assistance to navigate the insurance coverage process, identify affordability programs, and support patients with information and resources throughout their treatment journey.
Get a patient started

C1-INH=C1-inhibitor; DNA=deoxyribonucleic acid; RNA=ribonucleic acid.

Find the information that matters most to you

Choose what you would like to learn about DAWNZERA

Show me the clinical data Look at adverse events
Review the dosing schedule I want to start a patient

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.

References: 1. Data on file. Ionis Pharmaceuticals. 2. DAWNZERA. Prescribing information. Ionis Pharmaceuticals. 3. Riedl MA, Tachdjian R, Lumry WR, et al. Efficacy and safety of donidalorsen for hereditary angioedema. N Engl J Med. 2024;391(1):21-31. doi:10.1056/NEJMoa2402478 4. Tachdjian R, Riedl MA, Bordone L, et al. Long-term safety of donidalorsen for the treatment of hereditary angioedema: Results from the phase 3 open-label extension OASISplus study. Lecture presented: at EAACI Congress; May 31–June 3, 2024; Valencia, Spain. 5. Riedl MA, Bernstein JA, Jacobs JS, et al. Donidalorsen treatment of hereditary angioedema in patients previously on long-term prophylaxis. J Allergy Clin Immunol Pract. Published online July 17, 2025. doi:10.1016/j.jaip.2025.06.018 6. Riedl MA, Bordone L, Revenko A, et al. Clinical progress in hepatic targeting for novel prophylactic therapies in hereditary angioedema. J Allergy Clin Immunol Pract. 2025 Jul 17:S2213-2198(25)00599-9. doi:10.1016/j.jaip.2025.06.01 7. Ferrone JD, Bhattacharjee G, Revenko AS, et al. IONIS-PKKRx a novel antisense inhibitor of prekallikrein and bradykinin production. Nucleic Acid Ther. 2019;29(2):82-91. doi:10.1089/nat.2018.0754